Cytomegalovirus (CMV) is a frequently encountered infection following hematopoietic cell transplantation, and tissue invasive pneumonia is a dreaded complication of the virus in this population. In this review of CMV pneumonia, we address epidemiology, pathogenesis, diagnostics, current therapy, and strategies to prevent the development of CMV. We also review emerging treatment and prevention options for this challenging disease.
Introduction
Cytomegalovirus (CMV) continues to be a major cause of morbidity in hematopoietic cell transplant (HCT) recipients, 1,2 but of all CMV complications pneumonia is the most associated with significant mortality. 3 Prevention strategies aimed at limiting latent reactivation and viral replication have been successful in reducing the incidence of CMV pneumonia to approximately 4% in high-risk seropositive (Rþ) recipients, 4, 5 but changes in transplant practices, such as the expanded use of high-risk unrelated and cord blood donor grafts, have also defined new populations more likely to develop CMV invasive disease. 6 Unfortunately, even with potent antiviral therapy and advanced critical care management, death from CMV pneumonia remains unacceptably high. 3, 7 In this review, we address the epidemiology, pathogenesis, diagnostics, and review up-to-date treatment and prevention strategies for CMV pneumonia in HCT recipients. We also discuss ongoing research focused on novel treatment and prevention options, including antivirals in development. With the continued expansion of transplant programs throughout the world, an increased number of critical care physicians will have exposure to and responsibilities for diagnosing and treating this major posttransplant infectious complication. We hope that this review will serve as a state-of-the-art update on this infrequent yet important HCT complication for those with experience in transplantation and provide a foundation for those new to this unique immunocompromised population.
Epidemiology
Incidence. The incidence of CMV pneumonia in the early years of HCT, prior to the introduction of CMV prevention strategies, was around 10% to 35% after allogeneic transplantation and 1% to 6% in autologous transplant recipients. 8 The institution of preemptive strategies used at most centers in the United States (see Prevention section) have decreased the overall incidence of CMV disease in HCT recipients to around 5% to 8%. [3] [4] [5] The burden of disease has also shifted, as gastrointestinal (GI) disease is now considered the most common form of CMV disease in HCT; pneumonia is estimated to make up about onethird of the disease cases. 5, 9 The majority of cases of CMV pneumonia still occur in the early posttransplant period ( day þ 100), but the number of those occurring in the late period (after day 100) has increased. 3, 10 Late CMV disease occurs more frequently in patients who experienced CMV reactivation within the first 3 months after HCT (27), had graft-versus-host disease (GVHD), have persistent lymphopenia at day 100 (or low CD4 count), and in those Rþ recipients who received a CMV-seronegative (DÀ) donor graft (28). [9] [10] [11] [12] Outcomes Outcomes in patients who develop CMV pneumonia are generally very poor, even with the use of potent antiviral agents and aggressive critical care management. Rates of mortality associated with CMV pneumonia in the pretreatment era were nearly 100%, 13 but with the advent of ganciclovir (GCV) and other antiviral therapy options, the rates of death have fallen to approximately 30 to 50%. 1, 3, 14, 15 The need for respiratory and critical care support is strongly associated with increased mortality. 16 Interestingly, in some retrospective studies, rare patients with proven CMV pneumonia survive even without antiviral therapy, 1 suggesting different host factors may help determine survival postinfection.
Pre-and Posttransplant Risk Factors
Serologic Status (Donor and Recipient). The most prominent risk factor for CMV pneumonia is the transplant recipient's CMV serologic status prior to transplantation (Table 1) . Patients who are known to be Rþ are at the greatest risk of reactivation of latent virus through the transplant process and have the highest rates of subsequent CMV disease. 3, [17] [18] [19] [20] The relationship of donor serostatus in Rþ recipients remains controversial. [21] [22] [23] In contrast to their high-risk counterparts, RÀ patients who receive a positive donor graft (Dþ) have a much lower risk of CMV infection (12%-19%) and CMV disease (3%-5%). 20,24 Less than half of the Dþ/RÀ patients who are found to have invasive disease have pneumonia, and overall CMV pneumonia is an uncommon complication occurring in only about 1% of the patients with preemptive therapy. 20 Patients who are CMV DÀ/RÀ rarely develop evidence of CMV infection, and rates of CMV disease are very low (<1%; Table 1 ). 3, 25 Stem Cell Source. Multiple transplant-associated risk factors are linked to the development of CMV disease (see Table 1 ). When considering donor graft source, peripheral blood cells are thought to be associated with a lower risk of CMV reactivation and pneumonia than bone marrow grafts, 26 but umbilical cord blood transplant recipients appear to be at even higher risk of CMV disease due to significant delays in immune reconstitution. 6, 19, 27, 28 Patients receiving unrelated and mismatched donors are at higher risk of CMV disease, although this increased risk appears to be associated with the development of late disease. 14, [29] [30] [31] [32] Conditioning Regimen. Multiple transplant conditioning regimens have also been associated with the development of CMV disease. Earlier studies suggested that CMV complications were delayed in those undergoing nonmyeloablative conditioning when compared to myeloablative regimens, 14 but this has not been confirmed in larger cohort studies. 4, 31 T-cell depletion delays anti-CMV T-cell reconstitution 33 and has been associated with a higher risk of CMV complications in multiple populations. 15, 18, [34] [35] [36] [37] [38] Posttransplant Complications. Posttransplant complications are also known risk factors for the development of CMV disease. The development of acute and chronic graft GVHD is associated with the development of CMV disease. 3, 10, [39] [40] [41] [42] [43] Immunosuppressive strategies for acute and chronic GVHD prophylaxis have been related to higher risk of CMV infection. 44 T-cell therapies and mycophenolate mofetil delay CMV-specific T-cell responses and lead to more frequent CMV complications. [45] [46] [47] Interestingly, not all immunosuppressive therapy may have a negative effect on CMV, as sirolimus may have a protective role in CMV infection. 48 Detection of CMV in Blood. It is important to note that not all patients who have detectable CMV in their blood develop CMV disease and that nearly all patients with CMV pneumonia will have the evidence of CMV reactivation. 49 Determining the risk factors for progression from viral replication in blood to development of tissue invasive disease are challenging in this population, as most risk factors associated with CMV disease are also associated with CMV reactivation. The rates of progression from reactivation to CMV pneumonia have, however, been associated with leukopenia/lymphopenia at the time of reactivation and the development of a high-viral load during preemptive therapy. 50, 51 The viral kinetics of CMV post-HCT, particularly initial viral load and expansion kinetics, also appear to be strong predictors for the development of CMV disease. 51
Pathophysiology
Following primary infection, CMV becomes latent in the human host avoiding immune detection through multiplicative and diverse mechanisms. 52 Data suggest that bone marrowderived hematopoietic cells, granulocyte-macrophage progenitors, and peripheral blood monocytes serve as reservoirs for reactivation during immunosuppression. 20, [53] [54] [55] [56] [57] [58] In addition, murine models and human studies have demonstrated latency in lung alveolar macrophages and pulmonary epithelial cells. [59] [60] [61] The allogeneic process likely facilitates reactivation of CMV, 62 and major alterations in adaptive and innate immunity following transplantation lead to viral escape, replication, and eventual tissue invasion. CMV replication is linked to the degree of immunosuppression, and CMV pneumonia is more frequent and severe in HCT recipients than in most other immunosuppressed populations. 7 Pathogenesis of CMV pneumonia has been reviewed by others in detail, [63] [64] [65] but the mechanisms by which CMV invades the lung are unclear.
Immunopathology Hypothesis
The immunopathology hypothesis suggests that immune responses to CMV lead to pulmonary complications. 63, 64 Grundy and colleagues demonstrated that CMV proliferated extensively in the lung of athymic mice without development of pneumonitis and that once their T-cell immunity had recovered, pneumonitis developed rapidly. 64, 66 This theory is also thought to be supported by the lack of CMV pneumonia events in syngeneic transplants and in human immunodeficiency virus-infected patients with more profound CD4 deficiency. 64, 67 Cytopathological Hypothesis
The alternate cytopathological hypothesis suggests that CD8þ T cells are needed to protect against the development of CMV tissue invasion. 64, 65 Studies have implicated deficiencies in class I MHC-restricted, CMV-specific CD8þ T-lymphocyte responses in the progression to invasive disease. 65 This theory has been supported by clinical observations of severe CMV pneumonia occurring in murine studies and in patients treated with T-cell depleting agents. 15,68 Furthermore, it has been shown that neutralizing CD8þ T cells in immunosuppressed CMV-infected mice inhibited interstitial pulmonary involvement, 69 and that adoptive immunotherapy has been shown to abrogate CMV complications. 70 In addition, studies have demonstrated that marked reductions in CD4/CD8þ CMV specific T cells are associated with the development of late disease, and that low-dose CMV reactivation and subsequent immune education may prevent this complication. 11
Other Factors
There are also emerging data that support a role for natural killer (NK) cells in CMV complications following HCT, specifically with activating killer immunoglobulin-like receptor genotypes of donor cells. [71] [72] [73] The association between excess NK cells in bronchoalveolar lavage (BAL) from immunocompromised patients who died from CMV pneumonia suggests a role in aberrant immune responses to CMV. 74 At the same time, herpesvirus infections are much more likely to occur in children who lack NK cells but possess an intact adaptive immune system. 75 The endothelium is also thought to play a role in the pathophysiology of CMV lung involvement as infected endothelial cells upregulate adhesion molecules, allowing for leukocyte attachment and associated vascular damage. [76] [77] [78] It is unknown whether the driver of this associated endothelial injury is directly related to CMV, or whether toxicity from the transplant process (eg, total body irradiation) leads to such damage and subsequent CMV reactivation.
Diagnosis
Signs and Symptoms. CMV pneumonia is defined as the presence of clinical signs and symptoms of pneumonia or pulmonary disease combined with the detection of CMV from the lung. 79 Patients with CMV pneumonia present with findings consistent with pulmonary dysfunction including a nonproductive cough, dyspnea, and hypoxia; fever does not always have to be present. 80 Clinical examination may demonstrate prominent rales and tachypnea but may initially be unremarkable. Nevertheless, none of these signs or symptoms are classically associated with CMV pneumonia, and nearly all are only indicative of an ongoing pulmonary process.
Noninvasive Testing
There are no typical laboratory findings that confirm the diagnosis of CMV pneumonia. Patients with CMV pneumonia may have low oxygen saturations on arterial blood gas evaluation, and some patients may develop leukopenia or leukocytosis; these findings are not specific to CMV pneumonia. Detection of CMV in blood by CMV polymerase chain reaction (PCR) or the pp65 antigenemia test can be helpful but are not diagnostic even in the face of compatible symptoms. Although the majority of patients with CMV pneumonia will have CMV detected in blood, it can rarely occur without detection in blood. 49 
Radiology
The most common radiological sign is bilateral interstitial infiltrates on chest x-ray (see Figure 1 ). 80 Focal radiographic signs may also be absent in patients with documented CMV pneumonia. 7, 13, 81 Moreover, patients with neutropenia who are less likely to have abnormalities on conventional chest radiography may fail to detect lung infiltrates at an early stage; computed tomography (CT) scans have been shown to have higher sensitivity and assist in the early detection of more subtle pulmonary infiltrates. 82 The most common findings on CT are bilateral asymmetric ground glass, air space opacities, and small centrilobular nodules. 83 Although often a diffuse interstitial process on CT, CMV can also present less frequently as nodules or pulmonary consolidations. 84, 85 CMV may also present as a copathogen to other major infections, further limiting the specificity of radiologic findings.
Bronchoscopy/Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) has become the most frequent mechanism for the detection of CMV during the clinical management of HCT recipients. A number of laboratory and pathologic analyses are available on BAL fluid, and any one of these tests ( Figure 2 ) can be diagnostic for CMV pneumonia in the presence of appropriate clinical and radiologic findings; histopathology is not required. 79 Viral culture is performed by growing CMV in human fibroblastoid cell lines, but slow growth may require up to 4 weeks for diagnosis. The required time, low reproducibility, and low sensitivity of culture make this technique impractical for prompt diagnoses. Cytopathologic evaluation of inclusion bodies from BAL fluid has a high specificity but low sensitivity for CMV pneumonia, but immunohistochemical staining with anti-CMV antibodies may enhance sensitivity of this method. 86 Rapid detection of CMV can be performed by shell vial culture and/or direct fluorescent antigen testing (DFA). The shell vial method is a rapid culture technique that allows for identification of virus using monoclonal antibodies to immediate-early antigen within 24 hours and has been shown to be highly sensitive for the detection of CMV pneumonia. 87 This test, however, is operator dependent which limits widespread use in all but the largest centers. DFA is useful as a rapid test (within 1.5 hour) but lacks the sensitivity of other rapid tests. 88 Qualitative CMV PCR from BAL fluid has been shown to have a good negative predictive value but poor positive predictive value for the diagnosis of CMV pneumonia. 89, 90 Quantitative PCR has been suggested to have a higher sensitivity but the absence of established viral load cutoff of CMV for defining CMV disease limits the use of this technique. Furthermore, studies have demonstrated CMV DNA in BAL samples of asymptomatic HCT recipients, limiting interpretation of positive results. 91, 92 Still many centers currently utilize CMV PCR as part of their diagnostic strategy although it is not currently considered criteria for CMV pneumonia. 79 
Lung Biopsy
Histopathological diagnosis of CMV pneumonia from lung biopsy demonstrates typical intranuclear inclusions; CMV within cells may also be detected by immunohistochemical staining or in situ hybridization. 79 All lung biopsies and autopsy samples should also undergo routine shell viral testing for rapid diagnosis. Even though less likely to inform clinical care biopsy samples may also be held for CMV culture, as a positive result can be important for epidemiologic studies. Unfortunately in severe cases, lung biopsy is not always feasible, as rapid onset of respiratory failure, mechanic ventilation, or thrombocytopenia may limit access to this procedure. 93 The patchy nature of the disease suggests that fine-needle aspiration and less invasive pathologic sampling may miss clinically relevant disease. 94 
Differential Diagnosis
Infectious. Signs and symptoms of CMV pneumonia are not pathognomonic, and clinical manifestations and interstitial lung involvement may be caused by a multitude of other pathogens. Further complicating the picture is the uncertain role of CMV as either pathogen or bystander, as it can be detected in BAL specimens of patients with other confirmed pathogens. 24 Bacteria such as Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella species can all have similar subacute presentations. Respiratory viral pathogens, including influenza, parainfluenza, and respiratory syncytial virus, among others, can present with the findings that are similar to CMV; these infections may not always be associated with upper respiratory symptoms. 95 Other herpesviruses, albeit less frequently, can also present with pulmonary complications following transplantation. 96, 97 The role of human herpesvirus 6 in pulmonary disease remains somewhat unclear, but it can be seen as a copathogen in some patients. [98] [99] [100] [101] Adenovirus, another latent virus, has similar risk factors and can also present during the post-HCT period with similar radiographic and clinical findings. 102 The fungus Pneumocystis jiroveci can be challenging to distinguish from CMV pneumonia on clinical and radiographic findings alone, and although infrequent, CMV can also present with nodules or consolidation that resembles fungal pneumonia. 84, 85 Noninfectious. Noninfectious pulmonary complications can also present with signs and symptoms that may be similar to CMV. Idiopathic pneumonia syndrome presents with cough and tachypnea often seen in CMV pneumonia, and has associated multilobular infiltrates on chest x-ray or CT. 103 As a subgroup of these patients, patients with diffuse alveolar hemorrhage usually present more acutely. 103 Patients who develop noninfectious cryptogenic organizing pneumonia can also present with low-grade fever, nonproductive cough, and dyspnea similar to CMV pneumonia. 104 Radiologic manifestations can mimic viral pneumonia. 105 The development of pulmonary edema or patients who develop chemotherapy-associated pulmonary complications can also mimic CMV pneumonia. 106 Other medications, such as sirolimus, can lead to adverse pulmonary complications that may present with interstitial pneumonitis similar to CMV pneumonia or viral process. 107 Therapy Antiviral Therapy. The foundation for CMV pneumonia treatment is the early institution of antiviral therapy. CMV pneumonia following HCT, before the availability of current antivirals, was associated with a high mortality rate (nearly 100%). HCT recipients who receive early antiviral intervention may have improved outcome from CMV pneumonia. 108 Early treatment is thought to help control viral replication. This may help limit immune-related lung damage and reduce additional complications such as secondary infections and need for mechanical ventilation/ICU care. Still, antiviral therapy will not change the outcome in all patients, as even with CMV-specific antiviral therapy, death from CMV pneumonia remains an unavoidable outcome in many patients. 7, 16, 109 Therapy is focused on an induction phase (twice daily dosing) and a maintenance phase (once daily dosing) of treatment. At our center, patients with CMV pneumonia receive a minimum 3 weeks of induction therapy and at least 2 weeks of maintenance, but patients with more severe disease or slower responses to therapy may need prolonged therapy. First-line therapy for CMV pneumonia is intravenous (IV) GCV. Ganciclovir is a nucleoside analogue of 2 0 -deosygaunosine that undergoes initial phosphorylation by viral kinases encoded by CMV UL97 open reading frame (ORF). 110 The active form of the drug, triphosphorylated GCV, competitively inhibits DNA synthesis catalyzed by CMV DNA polymerase (encoded by the UL 54 ORF). 110 The use of GCV is limited by hematologic side effects, primarily neutropenia, which restrict its use in the preengraftment phase of transplantation. Intravenous GCV is recommended therapy for CMV pneumonia; although valganciclovir (the L-valyl ester of GCV) is available for oral dosing, it is not typically recommended for HCT recipients with CMV pneumonia. Valgancyclovir can be considered for maintenance therapy in lower risk patients who have demonstrated clinical response to therapy.
An alternate to GCV, foscarnet acts by inhibition of CMV viral polymerase. 110 Nephrotoxicity is the major adverse side effect of the drug and can lead to acute renal failure as well as mineral and electrolyte abnormalities. Because of these serious side effects, foscarnet is considered the second-line therapy but is preferred in patients with myelosuppression and for patients with known resistance to GCV. Cidofovir acts as a competitive inhibitor of DNA polymerase which has been shown to be effective in CMV ocular disease. 110, 111 Many consider cidofovir as a third-line agent due to its significant renal and hematologic toxicities. Combination therapy is sometimes considered in patients with evidence of drug resistance (reviewed in detail elsewhere 112 ) or in those with refractory disease.
Novel antiviral options have generally been studied in the context of CMV prophylaxis, so data on their efficacy in treatment of disease are inadequate to support the use of any of these agents as primary therapy. Maribavir (MBV) is an orally bioavailable drug that interferes with DNA synthesis of CMV and is also found to inhibit viral encapsidation and nuclear egress of viral particles by binding to UL97 viral protein kinases. 113 Maribavir has been used as salvage therapy for patients with proven CMV disease under individual emergency investigational new drug applications. In one recent report of CMV pneumonia treated with MBV, despite clearing CMV from the blood, the patient died from progressive disease. 114 A phase II treatment trial for refractory infections is currently underway. 115 Lipid-complex cidofovir (CMX-001) has shown promise against CMV, 116 but data on its use in CMV pneumonia are not currently available. Letermovir (AIC246), a novel anti-CMV drug that inhibits CMV replication through a mechanism that involves the viral terminase, 117 has been reported as a successful treatment in a patient with disseminated CMV disease. 118 Leflunomide, an agent approved for the treatment of rheumatoid arthritis, has CMV activity 119 and has also been attempted with mixed success in refractory cases. 120, 121 None of these agents are currently available, and none are Food and Drug Administration approved for treatment of CMV or CMV pneumonia.
Immunoglobulins
The use of both CMV-specific and nonspecific IV immunoglobulin (IVIG) are an additional component to consider during therapy. A number of clinical trials have assessed the role of IVIG in the treatment of CMV pneumonia. 122 Although early studies did not show effectiveness of IVIG as a stand-alone therapy, studies in the in late 1980s evaluating combination therapy with antivirals and various IVIG formulations demonstrated improved outcomes in patients with CMV pneumonia when compared to historical controls 123, 124 or to GCV or IVIG alone. 125 The small sample size of these early studies and recent evaluations under current preemptive strategies, however, suggest that combination therapy may provide minimal if any additional benefits to standard antiviral treatment. 16, 108, 126, 127 The high mortality seen in these patients, the limited side effects of IVIG treatment, and the lack of a randomized clinical trial comparing combination therapy versus antiviral therapy alone has led most to err on the side of caution and continue the routine use of combined antiviral and immunoglobulin therapy in the treatment of CMV pneumonia. For those centers that choose to use IVIG, it does appear that more costly CMV-specific IVIG may be no better than standard pooled IVIG preparations. 128 
Adoptive Immunotherapy
Newer laboratory techniques to treat severe viral infections include the development of ex vivo T cells that are specific to individual and multiple viruses. 70, [129] [130] [131] These therapies have been used to treat patients with severe infections. 132 Limited availability, the need for significant preparatory time, and high cost of these procedures limits their use to only major medical centers. The development of novel ''off-the-shelf'' methods for improving access and speed of delivery of these therapies should allow for future clinical trials.
Prevention
There are numerous reviews that discuss the advantages and disadvantages of different strategies to prevent CMV disease. 9, 25 In general prevention falls under 2 principles, primary prophylaxis and preemptive therapy and both have strengths and weaknesses.
Antiviral Prophylaxis
Antiviral prophylaxis has also been evaluated in a number of important clinical trials. The GCV prophylaxis has been shown to decrease the risk of early CMV disease, but patients in these trials also had associated increases in neutropenia and subsequent risk of bacterial and fungal infections. [133] [134] [135] [136] Prolonged antiviral exposure can also lead to selection of resistant CMV, 112 and may increase the risk of late disease events by delaying CMV immune recovery. 137 Prophylactic strategies among CMV-Rþ allogeneic transplant recipients lowered the incidence of CMV disease to 6% within the first 100 days after HCT but increased late complications (day þ 100 to 1 year) from 4% to 15% after the end of prophylaxis. 138 Acyclovir/valacyclovir, which have less systemic toxicity, can be used as an alternate to CMV-specific antiviral agents. Use of high-dose valacyclovir reduces the risk of CMV infection, 139 and in a randomized clinical trial it was as effective as GCV as chemoprophylaxis 140 ; others have shown benefits for disease prevention in high-risk populations when combined with preemptive therapy and other more aggressive prevention strategies. 6 Newer antiviral agents described in prior sections may have more tolerable side effect profiles and have been evaluated as options for chemoprophylaxis. Low-dose MBV appeared to be beneficial in a phase II trial, 141 but was ultimately shown to be ineffective as a prophylactic agent in a large multinational trial in HCT. 142 Both CMX001 and letermovir, appear promising, have shown reductions in CMV complications in high-risk Rþ allogeneic patients who underwent HCT. 143, 144 Side effects of letermovir were minimal, while CMX001 had notable GI side effects at high doses; neither drug had adverse effects on hematologic recovery. Although these data are encouraging, future phase III studies are needed to confirm these findings.
Preemptive Therapy Strategies
Most centers in the United States and worldwide use a preemptive approach 145 by which patients are screened weekly for CMV in blood and ''preemptively'' treated with CMVspecific antiviral therapy to prevent the development of disease. This approach has been shown to be effective in decreasing the risk of CMV disease (particularly pneumonia) either using pp65 or CMV PCR-based strategies. 5, 146 Specific cutoffs for institution of preemptive therapy depend on the type of laboratory screening method (pp65 vs serum PCR vs whole blood PCR) used at individual centers. Since not all patients who have CMV detected will develop disease, 20,147 institutions should develop specific thresholds for starting therapy. Once the threshold of detection has been met, patients are typically started on preemptive therapy with GCV or foscarnet until they clear CMV from their blood. For example at our center, patients are monitored weekly by CMV PCR through day 100, and started on therapy if they develop !500 copies copies/mL plasma. If patients are at high risk (T cell depleted or on !1 mg/kg of steroids) they are started at 100 copies. 31 All cord blood transplant recipients are tested twice weekly and started at any positive value. 6 Upon detection, patients are started on induction with GCV or foscarnet for a minimum of 2 weeks, followed by at least 1 week of maintenance. Patients are continued on induction until they have improvement in the viral copy numbers, and therapy is discontinued only after viral clearance. Continued surveillance is recommended in some patients at high risk of CMV complications after day 100, including those who develop early CMV reactivation and those on high-dose steroids for GVHD. 31 Immunoprophylaxis Immunoprophylaxis has been evaluated in recent metaanalysis, which found no benefit to either polyvalent or CMV-specific IVIG in the prevention of CMV pneumonia. 148 Since this strategy is both costly and with uncertain benefit, it is not recommended for CMV prevention in this population.
Cytomegalovirus Vaccines
Future options for prevention may include CMV vaccines that are currently in development. The CMV vaccine Trans-Vax was shown to decrease the rates of significant CMV viremia (!500 copies/mL) and the days free from viremia, but the rates of CMV disease did not differ between the vaccine and the placebo groups. 149 A phase III trial evaluating this vaccine in allogeneic HCT recipients is needed. A glycoprotein B vaccine has also been shown to be effective in decreasing the rate and severity of CMV viremia in other immunocompromised patients, 150 but no current data exist in HCT recipients. A novel tetanus-CMV fusion peptide vaccine has demonstrated immunogenicity in immunocompetent patients, but has not been tested in immunocompromised populations to date. 151 
Conclusions
Improved prevention strategies have decreased the incidence of this dreaded transplant complication, but CMV pneumonia remains a problem in patients undergoing HCT. The frequency of CMV reactivation and respiratory complications following transplantation, the diversity of etiologies of pulmonary disease, and the negative side effects associated with CMVspecific antiviral therapy strengthen the argument for an aggressive diagnostic approach in HCT recipients with respiratory symptoms and abnormalities on radiologic evaluation. Diagnosis of CMV pneumonia by standard techniques should be done as soon as possible. Future studies are needed to improve currently available diagnostics, including defining thresholds for CMV PCR from BAL and to develop noninvasive methods for diagnosing CMV disease. There is also a need to develop improved strategies for prevention which are nontoxic, easily administered, and effective. The development of the first new CMV antivirals in over 15 years suggests new treatment options are on the horizon. These novel antiviral agents and emerging CMV vaccines may also help provide improved methods for preventing this important complication.
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